Updated with analyst quote.
THE WOODLANDS, Tex. (TheStreet) -- Lexicon Pharmaceuticals (LXRX) are down 15% Monday following the announcement of a diabetes partnership between Merck (MRK) and Pfizer (PFE), raising worries that Lexicon may be having trouble nailing a diabetes deal of its own.
Merck and Pfizer -- more often viewed as bitter rivals -- are taking the unusual step of collaborating on the development and marketing of Pfizer's diabetes drug ertugliflozin, the companies announced Monday.
Lexicon is developing a similar drug, LX4211, but can't or won't advance it into phase III studies without a partner to help pay the costs. Merck choosing Pfizer immediately raised concerns that Lexicon might be having trouble finding a partner of its own.
@adamfeuerstein Bad news for $lxrx?Who is left to dance with them?— David Sobek (@dsobek) April 29, 2013
Safe to presume that $MRK did their DD on $LXRX drug before backing $PFE drug that is at similar stage in development?— Andrew G. (@BioDueDiligence) April 29, 2013Lexicon shares are down 18% to $1.86 in Monday trading. Pfizer's ertugliflozin and Lexicon's LX4211 belong to a new class of oral diabetes drugs known as sodium-dependent glucose transporter (SGLT) inhibitors that work by blocking the reabsorption of glucose into the bloodstream. The FDA approved the first SGLT inhibitor from Johnson & Johnson (JNJ), known as Invokana, at the end of March. A competing drug co-developed by Bristol-Myers Squibb (BMY) and AstraZeneca (AZN) was rejected by FDA last year due to safety concerns, although the drug was approved in Europe. Merck and Pfizer will share the costs of developing ertugliflozin as a standalone diabetes medicine but will also work to combine the new drug with Merck's biggest-selling diabetes drug Januvia. Lexicon has completed a phase II study of LX4211 but is seeking a Big Pharma partner to take on the responsibility of paying for phase III studies. The company was asked about the progress of partnership talks for LX4211 on its last quarterly confererence call held on Feb. 21. Jeffrey Wade, Lexicon's CFO: Sure. So we're continuing to make good progress in our partnership discussions for LX4211, it's a -- I mean, we're pleased with the progress, there is not anything that we're waiting on in particular for that. And we are continuing to plan for the advancement of LX4211 into Phase III this year with a partnership in place. So that continues to be our expectation. CEO Arthur Sands: So the only thing I'd add there is that you also asked if there were any particular issues or problems identified, and there are not. So we're very pleased with all the diligence proceeding as they've gone forward. It's a very thorough process and it takes time. But we do think we're on a good track there. Lexicon is presenting at an investor conference on Tuesday. No doubt, management will be asked for another LX4211 partnership update given Monday's Merck-Pfizer tie-up. "We had the chance to speak with LXRX [Lexicon] management this morning who remains very confident in the ongoing partnering process for LX4211 and that a Phase 3 program for the drug will start in 2H13, with a partner in place. Management stated that the MRK/PFE deal does not alter its go forward partnering plans in any way," wrote J.P. Morgan analyst Cory Kasimov, in an email note to clients. -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV